Dupixent (dupilumab) is generally a long-term, ongoing treatment with no set stopping point. Most people who respond well stay on it indefinitely, often for years, because it manages symptoms rather than curing the underlying condition. A five-year open-label extension study followed over 2,600 adults with moderate-to-severe atopic dermatitis on continuous dupixent, and the safety profile remained consistent throughout, suggesting the medication is designed for sustained use.
Why There’s No Fixed End Date
Dupixent works by blocking specific immune signals that drive inflammation. It doesn’t retrain your immune system or fix the root cause of conditions like eczema, asthma, or eosinophilic esophagitis. Instead, it keeps those inflammatory pathways turned down for as long as you’re taking it. Once you stop, the medication clears your system over roughly 9 to 13 weeks, and symptoms typically return.
The FDA-approved labeling does not specify a treatment duration or recommend a stopping point for any of its approved uses. Your doctor will periodically reassess whether the medication is still working and still necessary, but if it’s controlling your symptoms, the expectation is that you continue.
How Quickly It Starts Working
Most people notice improvement within the first few weeks, though the timeline varies by condition. For nasal polyps, about half of patients in clinical trials showed measurable improvement by week 4. For eczema and asthma, doctors typically evaluate whether the medication is working at around 16 weeks, with full benefits sometimes taking longer to appear.
For eosinophilic esophagitis, early symptom relief can begin around weeks 2 to 4, but guidelines recommend at least 24 weeks as an adequate trial period before deciding whether it’s effective. If you’re not seeing meaningful results by these checkpoints, your doctor may reassess, but the decision isn’t always straightforward. In one study of eczema patients, some who appeared to be non-responders on clinical measures still continued past week 16 because they experienced real improvements in itch, sleep, and quality of life that standard scoring didn’t capture. About 12% of patients in that study ultimately stopped between weeks 16 and 52 due to lack of efficacy or side effects.
The Dosing Schedule by Condition
For adults with atopic dermatitis, the standard regimen is a loading dose of 600 mg (two injections) at the first visit, followed by one 300 mg injection every two weeks. That every-two-week schedule is the ongoing maintenance rhythm for most adult patients.
Children are dosed differently based on weight. Kids aged 6 months to 5 years receive injections every four weeks with no loading dose. Older children and teens follow schedules that range from every two weeks to every four weeks depending on their weight. For asthma, adults and adolescents also follow an every-two-week injection schedule.
The FDA labeling does not include a tapering protocol or instructions for stretching doses further apart. Some doctors in clinical practice experiment with extending the interval between injections for patients in stable remission, but this is an off-label approach without formal guidelines supporting it.
What the Long-Term Data Shows
The longest published safety data for Dupixent comes from a five-year open-label extension study in adults with atopic dermatitis. Over 2,600 patients participated, initially receiving weekly doses before many transitioned to the standard every-two-week schedule. No new safety concerns emerged during the study, and the side effect profile remained the same as what was observed in shorter trials.
For asthma, data from combined trials spanning up to two years showed that benefits accumulated over time. At one year, 37.2% of patients met criteria for clinical remission, defined as having no severe flare-ups, no oral steroid use, stable or improved lung function, and good symptom control. By the end of year two, that number rose to 42.8% among patients who stayed on the medication continuously. Nearly 30% of patients maintained remission at both the one-year and two-year marks.
What Happens If You Stop
Dupixent is a large antibody molecule that your body breaks down gradually. After your last injection at the standard every-two-week dose, it takes roughly 10 to 11 weeks for the drug to become undetectable in your blood. During that washout period, symptoms generally begin to return as the medication’s effect fades.
This is one of the key reasons most patients stay on the medication long-term. Stopping doesn’t cause dangerous withdrawal effects, but the conditions Dupixent treats are chronic, and the inflammation it was suppressing tends to come back. If you’re considering stopping for any reason, including cost, side effects, or pregnancy planning, that conversation with your prescriber can help you weigh the risks of a break against the likelihood of a flare.
Insurance Renewals and Continued Coverage
Even though treatment is ongoing, your insurance company will likely require periodic reauthorization to confirm the medication is still medically necessary. A common structure is an initial approval lasting 12 months, after which renewals may be granted indefinitely. The specifics vary by insurer, but expect to provide updated documentation, such as symptom assessments or clinical notes, at least once a year to maintain coverage. Your prescriber’s office typically handles this process, though delays can sometimes cause gaps, so it’s worth asking about the renewal timeline well before your current authorization expires.